Research programme: AL-amyloid fibrillogenesis inhibitors - Neurochem

Drug Profile

Research programme: AL-amyloid fibrillogenesis inhibitors - Neurochem

Alternative Names: AL-amyloid fibrillogenesis inhibitors research programme - Neurochem

Latest Information Update: 02 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurochem
  • Developer BELLUS Health
  • Class
  • Mechanism of Action Amyloid fibril protein AL inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Amyloidosis

Most Recent Events

  • 02 May 2008 Discontinued - Preclinical for Amyloidosis in Canada (PO)
  • 07 Jul 2006 No development reported - Preclinical for Amyloidosis in Canada (PO)
  • 20 Jul 2000 Preclinical development for Amyloidosis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top